Viral-based therapies for liver cancer

HPB

Volumn 2, Issue 3, 2000, Pages 289-298

  Bennett, J J ^a   Fong, Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal cancer liver metastases; Hepatocellular carcinoma; Viral therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUOROURACIL; GANCICLOVIR; PRODRUG; PROTEIN P53; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; DNA INTEGRATION; DRUG SCREENING; DRUG TRANSFORMATION; GENE DELETION; GENE MUTATION; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LYSIS; NONHUMAN; RETROVIRUS; REVIEW; SUBSTITUTION THERAPY; SUICIDE GENE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VIRUS ATTENUATION; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0034473207     PISSN: 1365182X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1365-182X(17)30749-9     Document Type: Review

References (114)

1. Treatment of hepatocellular carcinoma: Too many options?
2. Hepatocellular carcinoma
3. Cancer Statistics, 2000
4. Haematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies
5. Failure patterns following curative resection of colonic carcinoma
6. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
7. Treatment of hepatocellular carcinoma
8. Liver resection for colorectal metastases
9. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on natural history
10. Dormant liver metastases: An experimental study
11. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
12. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
13. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
14. Gene therapy for liver tumors
15. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase
16. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
17. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
18. Gene therapy for colon cancer
19. The "bystander effect," tumor regression when a fraction of the tumor mass is genetically modified
20. Gene therapy of hepatoma: Bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir
21. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer
22. Clinical implications of the p53 tumor-suppressor gene
23. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
24. WAF1, a potential mediator of p53 suppression
25. Regulation of the human hsp70 promoter by p53
26. p53 status and the efficacy of cancer therapy in vivo
27. Relationship of p53 to the control of apoptotic cell death
28. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
29. p53: Puzzle and paradigm
30. Genetic mechanisms of tumor suppression by the human p53 gene
31. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line
32. Cytokine gene therapy for human tumors
33. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo
34. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma
35. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12
36. Cancer immunotherapy of established tumors with IL-12
37. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production
38. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon
39. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
40. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
41. Viruses as oncolytic agents: A new age for "therapeutic" viruses?
42. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma
43. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
44. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
45. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas
46. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207)
47. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
48. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector
49. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
50. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
51. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
52. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
53. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
54. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
55. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
56. Retroviridae: The viruses and their replication
57. Viral vectors for gene therapy
58. Gene delivery systems in surgery
59. Retroviruses as vectors
60. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
61. Methods of gene therapy
62. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors
63. The basic science of gene therapy
64. Advances in cancer gene therapy
65. Combination gene therapy for liver metastasis of colon carcinoma in vivo
66. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression
67. A defective HSV-1 vector expresses Escherichia coli β-galatosidase in cultured peripheral neurons
68. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology
69. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1
70. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
71. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
72. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
73. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy
74. Isolated-organ perfusion for local gene delivery: Efficient adenovirus-mediated gene transfer into the liver
75. Assessment of recombinant adenoviral vectors for hepatic gene therapy
76. Towards gene therapy for colorectal liver metastases
77. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma
78. Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer
79. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors
80. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors
81. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration
82. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas
83. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression
84. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene
85. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver
86. Regional 'pro-drug' gene therapy: Intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma
87. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
88. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene
89. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma
90. A "distant" bystander effect of suicide gene therapy: Regression of non-transduced tumors together with a distant transduced tumor
91. Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma
92. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma
93. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo
94. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas
95. Primary tumors of the liver
96. p53 gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus
97. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene
98. A Phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours
99. Gene therapy of metastatic cancer by in vivo retroviral gene targeting
100. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer
101. Gene therapy for hepatic micrometastasis of murine colon carcinoma
102. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma
103. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
104. The targeted expression of the human interleukin-2/interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells
105. Gene therapy with AdV-IL2 (TG 1021) in unresectable digestive adenocarcinoma. Phase I-II study, first inclusions
106. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): A phase I study
107. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma
108. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus
109. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
110. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytolytic herpes simplex virus type 1 (G207)
111. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1
112. A phase I clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumor injection in patients with recurrent head and neck cancer
113. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
114. Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: A phase I trial